このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Long-term Iron Absorption and Loss in Women

2026年9月28日 更新者:Tippawan Pongcharoen、Mahidol University

Long-term Iron Absorption and Loss in Overweight/Obese Thai Middle-aged Women

Obese people typically have chronic low-grade inflammation. Based on short-term studies, this inflammation could affect the absorption, utilization, storage, and mobilization of iron, and individuals with inflammation might develop iron deficiency (ID) and anemia when inadequacy of iron intake is presented. The double burden of malnutrition is nowadays emerging as a major public health concern in many countries, including Thailand. Understanding the association of chronic inflammation among people with overweight or obesity (OW/OB) with long-term iron absorption and loss is important for developing appropriate policies and programs to promote iron balance and, consequently, optimal iron status and health outcomes. Since previous reports among Thai women showed a high prevalence of OW/OB and anemia, this study will be conducted to determine the long-term iron absorption and loss among OW/OB free-living women using the iron isotope dilution method.

調査の概要

詳細な説明

  1. Research Objective To study iron absorption, loss, and long-term iron gain in overweight or obese middle-aged Thai women compared with normal-weight middle-aged Thai women.
  2. Research Methodology 2.1 Study design: This study is a longitudinal study comparing long-term iron absorption and loss between overweight or obese middle-aged Thai women and normal-weight middle-aged Thai women.

2.2 Study population: The study population consists of 64 women aged 40-50 years, divided into two groups: 32 overweight or obese women, and 32 normal-weight women.

2.3 Research Procedures 2.3.1 Before data collection: The research protocol is submitted for approval to the Central Institutional Review Board, Mahidol University. All data collectors will be trained prior to fieldwork. Upon receiving ethical approval, recruitment posters will be used to invite participants.

Screening process:

  1. Interested individuals meeting preliminary eligibility criteria will be informed about study details, sign informed consent, and schedule the first visit for screening and blood collection.

  2. Visit 1 (Screening):

    • Collect demographic and health history, measure weight, height, and body composition.
    • Collect 5 mL blood sample for Hb, SF, CRP, AGP, and hemoglobin typing.
    • Perform urine pregnancy test.
    • Administer one 400 mg albendazole tablet to prevent parasitic infection.

Iron isotope administration and follow-up:

2.3.2 Eligible participants will return within 1-2 weeks for the second visit.

Visit 2 (Month 0; M0):

Participants will consume a 15 mg ⁵⁷Fe isotope solution followed by 100 mg vitamin C drink, then fast for 3 hours.

A snack (plain yogurt and water) will be provided 1.5 hours after ingestion. A 24-hour dietary recall and semi-quantitative food frequency questionnaire (FFQ) will be conducted, with two additional 24-hour recalls by phone (2 weekdays and 1 weekend day).

Participants will then enter a 1-year equilibration period, recording illness and menstrual data monthly. The research team will monitor via LINE or email.

Visit 3 (Month 9; M9):

Collect fasting blood (5 mL) for Hb, glucose, HbA1c, and lipid profile; measure weight, BP, and conduct 24-hour recall (plus two by phone).

Visit 4 (After 1 year; WK0):

Collect fasting blood (10 mL) for Hb, SF, TfR, CRP, AGP, erythrocyte isotopic enrichment.

Measure weight, body composition, pregnancy test, and dietary recalls (3 days) and FFQ.

Visits 5-7 (WK8, WK16, WK24):

For eligible participants, repeat blood tests (7 mL) for Hb, SF, TfR, CRP, AGP, isotopic enrichment, anthropometry, pregnancy test, 3-day dietary recalls, and FFQ.

2.4 Research Instruments

  1. General information and medical history questionnaire, 24-hour dietary recall, and FFQ.

  2. Illness and menstrual record forms.

  3. Anthropometry and clinical measures:

    • Weight: InBody digital scale
    • Height: Harpenden stadiometer
    • Body composition: Bioelectrical Impedance Analyzer (BIA; InBody)
    • Blood pressure: Omron digital sphygmomanometer
  4. Laboratory analyses:

    • Hb: Complete Blood Count (CBC) using flow cytometry
    • SF, TfR, CRP, AGP: ELISA (SFa calculated from SF, CRP, AGP)
    • Hemoglobin typing: Capillary electrophoresis
    • Fasting glucose: Enzymatic method
    • HbA1c: Turbidimetric inhibition immunoassay
    • Lipids: Enzymatic colorimetric and homogeneous methods
    • Iron isotopes: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 2.5 Data Analysis Nutrient intake (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated using INMUCAL software.

Dietary patterns will be analyzed using Principal Component Analysis (PCA).

The average iron absorption (Fe_abs) over the study period will be calculated as:

Feabs=kabs×FetotalFe_{abs} = k_{abs} \times Fe_{total}Feabs=kabs×Fetotal where Fe_total is the total body iron at the midpoint estimated from the regression of Fe_total over time, and k_abs is the fractional iron absorption rate derived from the slope of the regression line of ln(⁵⁷Fe) vs. time.

Average iron loss (Fe_loss) is calculated similarly:

Feloss=kloss×FetotalFe_{loss} = k_{loss} \times Fe_{total}Feloss=kloss×Fetotal

Iron gain (Fe_gain) is calculated as:

Fegain=Feabs-FelossFe_{gain} = Fe_{abs} - Fe_{loss}Fegain=Feabs-Feloss Differences between groups in general characteristics, biochemical parameters, and iron absorption/loss slopes will be tested using Independent t-test or Mann-Whitney U-test, as appropriate.

A Linear Mixed-Effects Model will be used to analyze group differences in longitudinal changes of iron absorption, loss, and gain.

Statistical significance will be set at p < 0.05.

研究の種類

観察的

入学 (推定)

64

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Aree Prachansuwan, Ph.D.
  • 電話番号:+66890060602

研究場所

      • Nakhon Pathom、タイ、73170
        • 募集
        • Institute of Nutrition
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年~50年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

サンプリング方法

非確率サンプル

調査対象母集団

The study population will consist of 64 women aged 40-50 years, divided into two groups: 32 participants who are overweight or obese, and 32 participants with normal weight.

説明

Inclusion Criteria:

  • Normal weight group

    1. Aged 40-50 years
    2. Normal weight (BMI 18.5-22.9 kg/m²)
    3. Hb ≥12.0 g/dL and inflammation-adjusted SFa <50.0 µg/L
    4. CRP <5.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years
  • Overweight/obese group

    1. Aged 40-50 years
    2. Overweight or obese [Body Mass Index (BMI) ≥25.0 kg/m²] - the BMI cut-off follows the agreement of countries under the Coordinated Research Project (CRP) E43038 "Using the iron isotope dilution technique to assess the influence of inflammation on long-term iron absorption and loss," supported by the IAEA
    3. Hemoglobin (Hb) ≥12.0 g/dL and inflammation-adjusted serum ferritin (SFa) <50.0 µg/L
    4. C-reactive protein (CRP) between 5.0-25.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years

Exclusion Criteria:

  • Normal weight group

    1. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    2. Having metabolic NCDs (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    3. Pregnant, breastfeeding, or planning pregnancy during the study
    4. Chronic infectious disease (e.g., tuberculosis, AIDS)
    5. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    6. Taking vitamin or mineral supplements during or within two weeks prior to the study
    7. Participating in a weight-loss program
    8. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    9. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    10. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)
  • Overweight/obese group

    1. Obesity class II (BMI ≥35.0 kg/m²) with high health risk
    2. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    3. Having metabolic noncommunicable diseases (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    4. Pregnant, breastfeeding, or planning pregnancy during the study
    5. Chronic infectious disease (e.g., tuberculosis, AIDS)
    6. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    7. Taking vitamin or mineral supplements during or within two weeks prior to the study
    8. Participating in a weight-loss program
    9. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    10. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    11. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Normal weight

BMI 18.5-22.9 kg/m2

Overweight or obesity

BMI 25-35 kg/m2

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Mean long-term iron absorption (Fe abs)
時間枠:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).

Calculated over the duration of the study as follows: Fe abs = k abs x Fe total Where Fe total is the total body iron at the midpoint, calculated from the linear regression of Fe total versus time across each measurement point; and k abs is the fraction of total body iron absorbed per unit of time (derived from the slope of the linear regression equation of ln 57 Fe versus time).

57 Fe isotope will be measured using Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).
Mean long-term iron loss (Fe loss)
時間枠:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated in the same manner as iron absorption: Fe loss = k loss x Fe total Where k loss is the fraction of total body iron lost per unit of time.

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Iron gain (Fe gain)
時間枠:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated as net iron balance: Fe gain = Fe abs - Fe loss

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

二次結果の測定

結果測定
メジャーの説明
時間枠
Weight (kg)
時間枠:Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Weight will be measured in kg (to the nearest 0.1 kg) using an Inbody digital weighing scale.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Height (cm)
時間枠:Visit 1 (Screening)

Height will be measured to the mearest 0.1 cm using a Harpenden stadiometer.

Visit 1 (Screening)
Body Mass Index (BMI, kg/m²)
時間枠:Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

BMI will be calculatedn body weight in kilograms divided by height in meters squared.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Body composition (fat mass)
時間枠:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Body composition (fat mass) will be measured using the Bioelectrical Impedance Analyzer (BIA; InBody).

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Nutrient intakes
時間枠:Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Nutrient intakes (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated from 3-day 24-hr dietary recalls using INMUCAL software.

Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Dietary pattern
時間枠:Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Dietary patern from FFQ will be analyzed using the Principal Component Analysis (PCA)

Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Hemoglobin (Hb, g/L)
時間枠:Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Hb concentration will be assessed using flow cytometry

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Serum ferritin (SF, µg/L)
時間枠:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

SF will be measured using Enzyme-linked immunosorbent assay (ELISA)

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
serum transferrin receptor (sTfR µg/L)
時間枠:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

sTfR will be assessed using ELISA

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
c-reactive protein (CRP, mg/L)
時間枠:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

CRP will measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
alpha-1 acid glycoprotein (AGP, g/L)
時間枠:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

AGP will be measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Glycated hemoglobin (HbA1c, %)
時間枠:Visit 3 (Month 9)

HbA1c wil be measured by Turbidimetric inhibition immunoassay

Visit 3 (Month 9)
Lipid profile
時間枠:Visit 3 (Month 9)

Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) will be measured using Enzymatic colorimetric and homogeneous methods.

Visit 3 (Month 9)
Blood pressure (BP, mmHg)
時間枠:Visit 3 (Month 9)

BP will be measured using Omron digital sphygmomanometer

Visit 3 (Month 9)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Veronica LOPEZ TEROS, Ph.D.、Internation Atomic Energy Agency

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年5月8日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2028年8月31日

試験登録日

最初に提出

2026年8月6日

QC基準を満たした最初の提出物

2026年9月28日

最初の投稿 (実際)

2026年10月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

There has been ongoing discussion regarding collaboration on data analysis and publication among countries that have conducted studies supported by the International Atomic Energy Agency (IAEA).

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する